在心力衰竭患者中,elabela/toddler 是一个不良的预后标记吗?
U Küçük1, B Kırılmaz1, H Kaya1
1Department of Cardiology, Faculty of Medicine, Çanakkale Onsekiz Mart University, Çanakkale, Turkey.
Hippokratia
|October 7, 2024
概括
在心力衰竭患者中,心力衰竭/幼儿 (ELA-32) 水平升高可预测心血管死亡率和住院病例. 这一发现为使用ELA-32作为生物标志物的HFrEF预后提供了新的见解.
科学领域:
- 心血管医学 心血管医学
- 生物标志物 生物标志物
- 心脏衰竭研究研究
背景情况:
- 埃拉贝拉/托德勒 (ELA-32),一种内源性阿佩林受体连接体,在心力衰竭 (HF) 患者中升高.
- 在HF患者中ELA水平升高的预后意义以前是未知的.
- 降低射出率心力衰竭 (HFrEF) 是一种主要的心血管疾病,需要预后标志物.
研究的目的:
- 研究HFrEF患者的血ELA-32水平和预后之间的相关性.
- 确定ELA-32是否可以作为HFrEF中不良心血管事件的预测生物标志物.
主要方法:
- 一项涉及73名HFrEF患者和77名健康对照者的病例控制横截面研究.
- 在入院时测量血ELA-32水平.
- 随访时间平均为7.48个月,以评估心血管死亡率和与HF相关的住院治疗.
主要成果:
- 与对照组相比,HFrEF患者的ELA-32水平显著更高,随着NYHA晚期的进展而增加.
- 血清ELA-32切断值为8.25 ng/mL,显示出高灵敏度 (76%) 和特异性 (82%) 预测研究终点 (AUC:0.84).
- 升高的ELA-32 (≥8.25 ng/mL) 独立地与心血管死亡率 (HR=2.556) 和与高血压相关的住院住院的风险增加有关.
结论:
- 增加的ELA-32水平与HFrEF患者的HF相关住院和心血管死亡率独立相关.
- ELA-32成为HFrEF的一个新的和重要的预后生物标志物.
- 这项研究提供了第一个证据,将ELA-32水平与HFrEF的不良结果联系起来.
更多相关视频
08:38Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition
Published on: July 21, 2023
1.1K
08:22Measuring Cardiac Autonomic Nervous System ANS Activity in Toddlers - Resting and Developmental Challenges
Published on: February 25, 2016
15.4K
相关概念视频
01:30Heart Failure IV: Classification and Diagnostic Evaluation
2
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
2
01:26Heart Failure III: Clinical Manifestations
3
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
3
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:30Heart Failure V: Nursing Interventions
2
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
2
01:22Heart Failure VI: Adjunct Therapies
5
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
5